Liu G, Zhu M, Zhang M, Pan F. Rising position of IGF-1 in prostate most cancers: a promising biomarker and therapeutic goal. Cancers. 2023;15:1287.
Brahmkhatri VP, Prasanna C, Atreya HS. Insulin-like development issue system in most cancers: novel focused therapies. Biomed Res Int. 2015;2015:538019.
Pierce JR, Martin BJ, Rarick KR, Alemany JA, Staab JS, Kraemer WJ, et al. Development hormone and insulin-like development Issue-I molecular weight isoform responses to resistance train are sex-dependent. Entrance Endocrinol (Lausanne). 2020;21:571.
Ascenzi F, Barberi L, Dobrowolny G, Villa Nova Bacurau A, Nicoletti C, Rizzuto E, et al. Results of IGF-1 isoforms on muscle development and sarcopenia. Getting old Cell. 2019;18:e12954.
Dai Z, Wu F, Yeung EW, Li Y. IGF-IEc expression, regulation and organic operate in several tissues. Development Horm IGF Res. 2010;20:275–81.
Matheny RW Jr., Nindl BC, Adamo ML. Minireview: Mechano-growth issue: a putative product of IGF-I gene expression concerned in tissue restore and regeneration. Endocrinology. 2010;151:865–75.
Schlegel W, Raimann A, Halbauer D, Scharmer D, Sagmeister S, Wessner B, et al. Insulin-like development issue I (IGF-1) Ec/Mechano Development factor-a splice variant of IGF-1 inside the development plate. PLoS One. 2013;8:e76133.
Armakolas A, Philippou A, Panteleakou Z, Nezos A, Sourla A, Petraki C, et al. Preferential expression of IGF-1Ec (MGF) transcript in cancerous tissues of human prostate: proof for a novel and autonomous development issue exercise of MGF E peptide in human prostate most cancers cells. Prostate. 2010;70:1233–42.
Armakolas A, Kaparelou M, Dimakakos A, Papageorgiou E, Armakolas N, Antonopoulos A, et al. Oncogenic position of the Ec peptide of the IGF-1Ec Isoform in prostate most cancers. Mol Med. 2015;21:167–79.
Armakolas A, Dimakakos A, Loukogiannaki C, Armakolas N, Antonopoulos A, Florou C, et al. IL-6 is related to IGF-1Ec upregulation and Ec peptide secretion, from prostate tumours. Mol Med. 2018;24:6.
Savvani A, Petraki C, Msaouel P, Diamanti E, Xoxakos I, Koutsilieris M. IGF-IEc expression is related to superior medical and pathological stage of prostate most cancers. Anticancer Res. 2013;33:2441–5.
Xoxakos I, Petraki C, Msaouel P, Armakolas A, Grigorakis A, Stefanakis S, et al. Expression of Kisspeptin (KISS1) and its Receptor GPR54 (KISS1R) in prostate most cancers. Anticancer Res. 2020;40:709–18.
Bastide C, Bagnis C, Mannoni P, Hassoun J, Bladou F. A Nod Scid mouse mannequin to check human prostate most cancers. Prostate Most cancers Prostatic Dis. 2002;5:311–5.
Tanaka S, Kobayashi W, Haraguchi M, Ishihata Okay, Nakamura N, Ozawa M. Snail1 expression in human colon most cancers DLD-1 cells confers invasive properties with out N-cadherin expression. Biochem Biophys Rep. 2016;8:120–6.
Li H, Batth IS, Qu X, Xu L, Tune N, Wang R, et al. IGF-IR signaling in epithelial to mesenchymal transition and focusing on IGF-IR remedy: overview and new insights. Mol Most cancers. 2017;16:6.
Osher E, Macaulay VM. Therapeutic focusing on of the IGF axis. Cells. 2019;8:895.
Simpson A, Petnga W, Macaulay VM, Weyer-Czernilofsky U, Bogenrieder T. Insulin-Like Development Issue (IGF) pathway focusing on in most cancers: position of the IGF axis and alternatives for future mixture research. Goal Oncol. 2017;12:571–97.
Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, et al. Twin IGF-I/II–neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumour development. Most cancers Res. 2011;71:1029–40.
Olmos D, Okuno S, Schuetze SM, Paccagnella ML, Yin D, Gualberto A, et al. Security, pharmacokinetics and preliminary exercise of the anti–IGF-IR antibody CP-751,871 in sufferers with sarcoma. JCO Suppl. 2008;6:122.
Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, et al. A part I research of weekly R1507, a human monoclonal antibody insulin-like development factor-I receptor antagonist, in sufferers with superior stable tumours. Clin Most cancers Res. 2010;16:2458–65.
Al-Samerria S, Radovick S. The position of Insulin-like Development Issue-1 (IGF-1) within the management of neuroendocrine regulation of development. Cells. 2021;10:2664.
Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, et al. Circulating ranges of IGF-1 instantly regulate bone development and density. J Clin Investig. 2002;110:771–81.
Prosser CG. Insulin-like development elements in milk and mammary gland. J Mammary Gland Biol Neoplasia. 1996;1:297–306.
Hong H, Cui ZZ, Zhu L, Fu SP, Rossi M, Cui YH, et al. Central IGF1 improves glucose tolerance and insulin sensitivity in mice. Nutr Diabetes. 2017;7:2.
Kandalla PK, Goldspink G, Butler-Browne G, Mouly V. Mechano Development Issue E peptide (MGF-E), derived from an isoform of IGF-1, prompts human muscle progenitor cells and inducean enhance of their fusion potential at completely different ages. Mech Ageing Dev. 2011;132:154–62.
Hill M, Wernig A, Goldspink G. Muscle satellite tv for pc (stem) cell activation throughout native tissue harm and restore. J Anat. 2003;203:89–99.
Hill M, Goldspink G. Expression and splicing of the insulin-like development issue gene in rodent muscle is related to muscle satellite tv for pc (stem) cell activation following native tissue injury. J Physiol. 2003;549:409–18.
Stavropoulos A, Varras M, Philippou A, Vasilakaki T, Varra VK, Varra FN, et al. Immunohistochemical expression of insulin-like development factor-1Ec in main endometrial carcinoma: Affiliation with PTEN, p53 and survivin expression. Oncol Lett. 2020;20:395.
Karagiannis AK, Philippou A, Tseleni-Balafouta S, Zevolis E, Nakouti T, Tsopanomichalou-Gklotsou M, et al. IGF-IEc expression is related to superior differentiated thyroid most cancers. Anticancer Res. 2019;39:2811–9.
Christopoulos PF, Msaouel P, Koutsilieris M. The position of the insulin-like development factor-1 system in breast most cancers. Mol Most cancers. 2015;14:43.
Alexandraki KI, Philippou A, Boutzios G, Theohari E, Koutsilieris M, Kassiani Delladetsima I, et al. IGF-IEc expression is elevated in secondary in comparison with main foci in neuroendocrine neoplasms. Oncotarget. 2017;8:79003–11.
Alagaratnam S, Loizidou M, Yang SY, Fuller B, Ramesh B. Elevated expression of IGF-1Ec with rising colonic polyp dysplasia and colorectal most cancers. J Most cancers Res Clin Oncol. 2020;146:2861–70.
